MARKET WIREReuters • 2h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why TKNO Stock surged +2.93% Today — RQD Quant Desk Flash
$8.09 +2.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $8.12
Alpha Teknova Inc. (TKNO) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $499.2M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $8.12 (+0.34%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for TKNO)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY TKNO SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+14/20 pts (32% of score)
Altman Z-Score 6.93 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9
▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (23% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$8.84-19.9% Next Q
52
Q2 (-2Q)Grade D$7.08-9.3% Next Q
49
Q3 (-1Q)Grade D$6.42+26% Next Q
47
CurrentGrade D$8.09-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a TKNO Turnaround Squeeze
While TKNO currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.71) and Max Pain ($8.49) forces dealer call-delta covering toward $9.95.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $TKNO• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “TKNO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why TKNO Stock surged +2.93% Today — RQD Quant Desk Flash
Alpha Teknova Inc. (TKNO) surged +2.93% to $8.09, trading at 82% of its 52-week range ($1.91 – $9.48). Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 82% of its 52-week range ($1.91 – $9.48) with RSI-14 at 48.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $8.09 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 33.2% gross margin and $0 annual free cash flow.
Live TKNO Headlines & Catalysts
MARKET WIRECNBC • 4h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 4h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 7h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 8h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 9h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring TKNO)
- ✓Walkthrough of TKNO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
TKNO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +127.89%▲ ASCENDING CHANNEL
2026-10-30O $8.01H $8.09L $7.11C $8.09VOL 651.1K
RES: $10.62SUP: $5.04SMA50: $7.71SMA200: $4.88
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
TKNO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +7.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on TKNO today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for TKNO. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for TKNO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (TKNO)
Health Care Rank #507 of 1016
⚔️ NNNN vs TKNO Full Matrix →
1. Head-to-Head Health Care Peer Comparison (TKNO vs. NNNN, MYGN, ACHV, QDEL)
Industry: Biotechnology: In Vitro & In Vivo Diagnostic Substances (18 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Alpha Teknova Inc. (TKNO) ranks #507 by composite RQD confidence (44/100, grade D) and #453 by equity capitalization ($499.2M). Within this direct 5-issuer industry benchmark cohort, NNNN leads on earnings valuation at 83.6x trailing P/E, while NNNN leads on capital efficiency and profitability with 17.0% ROIC and 87.2% gross margin. NNNN currently holds the highest overall quantitative score in the immediate peer group at 45/100 (D) compared with TKNO at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| TKNO
ACTIVE
Alpha Teknova Inc. | D | 44/100 | — | 33.2% | -21.3% | +2.93% | $499.2M | Benchmark Subject |
| NNNN Anbio Biotechnology (Class A) | D | 45/100 | 83.6x | 87.2% | 17.0% | -3.12% | $535.3M | /nnnn-vs-tkno → |
| MYGN Myriad Genetics Inc. | D- | 39/100 | — | 69.9% | -35.0% | +0.60% | $638.0M | /mygn-vs-tkno → |
| ACHV Achieve Life Sciences Inc. | D | 44/100 | — | — | -35.0% | +4.96% | $739.9M | /achv-vs-tkno → |
| QDEL QuidelOrtho Corporation | E | 30/100 | — | — | -35.0% | -1.78% | $943.6M | /qdel-vs-tkno → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001850902In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alpha Teknova Inc. (TKNO) reported GAAP revenue of $40.5M (+7.4% vs. FY2024 revenue of $37.7M , and +10.5% cumulative change since FY2023) , GAAP net income of -$17.3M, operating cash flow of -$8.6M, and free cash flow of -$9.8M (+27.5% YoY). On the balance sheet, TKNO closed FY2025 with $103.6M in total assets against $0 in total debt (Altman Z-Score: 6.93, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.5M | -$17.3M | -$8.6M | -$9.8M | $103.6M | — |
| FY2024 (FY) | 2024-12-31 | $37.7M | -$26.7M | -$12.4M | -$13.5M | $118.8M | — |
| FY2023 (FY) | 2023-12-31 | $36.7M | -$36.8M | -$18.8M | -$18.8M | — | — |
3. TKNO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs TKNO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Alpha Teknova Inc. (NASDAQ: TKNO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $8.09 (+2.93% 1D, market cap $499.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, TKNO ranks #507 in composite RQD confidence.
How does TKNO compare to NNNN and MYGN in the Health Care sector?
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), TKNO carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 33.2%, and ROIC of -21.3%. By comparison, NNNN (Anbio Biotechnology (Class A)) holds a D grade (45/100 RQD, P/E 83.6x, ROIC 17.0%, cap $535.3M) and MYGN (Myriad Genetics Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -35.0%, cap $638.0M). Among the 5-stock peer group, NNNN leads on earnings multiple (83.6x) while NNNN leads on capital efficiency (17.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for TKNO?
Per TKNO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001850902), Alpha Teknova Inc. generated $40.5M in revenue (+7.4% YoY), -$17.3M in net income, and -$9.8M in free cash flow against $103.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is TKNO trading relative to its 50-day, 200-day, and 52-week technical levels?
TKNO last traded at $8.09 (+2.93% on volume of 679,716 shares), positioning the stock +4.93% above its 50-day simple moving average ($7.71) and +65.78% above its 200-day simple moving average ($4.88). Across its 52-week range of $1.91 to $9.48, TKNO sits at the 81.6% percentile with a 14-day RSI of 48.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($7.08 to $9.10).
TKNO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is TKNO stock moving today?
Why TKNO Stock surged +2.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-21% return on capital) under elevated 10-year interest-rate pressure.